Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.
Catherine Van PoznakEvan L ReynoldsCherry L EstiloMimi HuBryan Paul SchneiderDaniel Louis HertzChristina GerschJacklyn ThibertDafydd ThomasMousumi BanerjeeJames M RaeDaniel F HayesPublished in: Oral diseases (2020)
We observed patients with ONJ were more likely to have been exposed to bevacizumab and zoledronic and identified potential genetic predictors that require validation prior to clinical translation.